TriLink BioTechnologies ® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap ® mRNA Capping Technology
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
“CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430716807/en/
Contact information
Liz Robinson of CG Life
TriLink BioTechnologies
lrobinson@cglife.com
312-997-2436
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PathAI Announces Early Access Program to Drive Adoption of AISight Image Management System in Anatomic Pathology Laboratories Across Mainland Europe21.5.2024 09:00:00 CEST | Press release
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for laboratories in the United States, which attracted over 50 laboratories with many exploring long-term use of PathAI’s AISight Image Management System and broad menu of AI Products. As part of the EAP, AP Laboratories in Europe can trial AISight, a modern and cloud-based digital pathology solution compliant with GDPR, as well as conduct and publish real-world validation studies of PathAI’s AI Products such as ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1, and AIM-HER2.2 “We are thrilled to commence a more dedicated focus to bring AISight Image Management System to labs in Europe. We have continued to make improvements on the platform with input from our first set of commercial customers in the U.S. We are excited to partner with Europea
42% of Companies Ready to Adopt Digital ID, New Regula Study Shows21.5.2024 09:00:00 CEST | Press release
As more countries adopt the concept of digital identity, regulators are keen to showcase their plans and successes. But what do businesses think about this shift? To find out, Regula, a global developer of forensic devices and identity verification (IDV) solutions, commissioned a study to survey companies across different regions and industries to get a sense of their readiness, concerns, and expectations for digital identities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521226453/en/ Regula study shows, that the majority of companies around the world are fully aware of digital IDs. Moreover, there are organizations, that have already started integrating this technology in their IDV procedures. (Graphic: Business Wire) Digital identity is considered to be a way to improve the efficiency and security of services, reduce fraud, and enhance access to public services, ensuring that they are delivered quickly and to the ri
Aqara Introduces Smart Wall Outlet to the European Market: Elevating Convenience and Energy Efficiency21.5.2024 09:00:00 CEST | Press release
Aqara, a leading provider of smart home solutions, is thrilled to announce the availability of its Wall Outlet H2 EU, expanding the Company’s energy management product lineup in the European market. This 16 Amp Type F (Schuko) smart wall outlet empowers homeowners to automate and remotely control their home appliances and devices, enhancing both convenience and energy efficiency. The Aqara Wall Outlet H2 EU integrate smart technologies directly into the wall, providing a seamless and aesthetically pleasing solution without sacrificing connectivity and functionality. Compatible with popular 55 mm wall plate designs like Schneider Merten System M, the outlet is versatile for use in both single and multi-gang setups, making it an ideal option for most homes. Built upon the Zigbee 3.0 protocol, the Wall Outlet H2 EU supports Matter-over-Bridge, ensuring local integration with a wide range of smart home platforms, including Amazon Alexa, Apple Home, Google Home, Samsung SmartThings, Homey,
OneStock Announces $72 Million Investment to Help Brands Unlock Their Full Omnichannel Potential21.5.2024 08:00:00 CEST | Press release
OneStock SAS, a leading provider of Order Management Systems (OMS), today announced a $72 million investment from global growth equity investor Summit Partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520891262/en/ Founders Benoit Baccot and Romulus Grigoras, OneStock (Photo: Business Wire) OneStock was founded in 2015 by CEO, Romulus Grigoras, and CTO, Benoit Baccot, to help retailers and brands navigate the increasing complexity of the omnichannel landscape and enhance overall customer experience. The company’s cloud-native solution provides a centralised platform designed to manage end-to-end order fulfillment and visibility and empower retailers to offer a seamless ‘buy anywhere, deliver anywhere, return anywhere’ experience to customers. "Since the beginning, OneStock has been dedicated to creating smarter and more sustainable shopping experiences, and our partnership with Summit marks a thrilling new chapter
Janus Henderson Investors intends to reject Forseti III AB’s offer to the shareholders of Karnov Group AB21.5.2024 08:00:00 CEST | Press release
Janus Henderson manages funds that own 3,754,750 shares in Karnov Group AB. We consider the SEK 84 per share offer from Forseti III AB to be far below Karnov’s intrinsic value and intend to reject the offer. This decision is in line with our value of “Clients Come First – Always” because at Janus Henderson we believe in doing all we can to deliver the best outcomes for our clients and their clients, including zealous advocacy based on rigorous fundamental research in cases such as this. About Janus Henderson Janus Henderson Group is a leading global active asset manager dedicated to helping clients define and achieve superior financial outcomes through differentiated insights, disciplined investments, and world-class service. As of March 31, 2024, Janus Henderson had approximately US$353 billion in assets under management, more than 2,000 employees, and offices in 24 cities worldwide. The firm helps millions of people globally invest in a brighter future together. Headquartered in Lond
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom